Virkningen af Xagrid har været genstand for fire kliniske undersøgelser, der omfattede et antal patienter med forskellige myeloproliferative sygdomme (sygdomme, hvor knoglemarven producerer for mange celler), herunder næsten 3 000 patienter med ET.
The effectiveness of Xagrid has been studied in four clinical studies involving a number of patients with various myeloproliferative diseases (diseases where the bone marrow produces too many cells) including nearly 3,000 patients with ET.